Phaseline

Targets › CLN5

CLN5 (Bis(monoacylglycero)phosphate synthase CLN5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2028.

[Bis(monoacylglycero)phosphate synthase CLN5, secreted form]: Catalyzes the synthesis of bis(monoacylglycero)phosphate (BMP) via transacylation of 2 molecules of lysophosphatidylglycerol (LPG). BMP also known as lysobisphosphatidic acid plays a key role in the formation of intraluminal vesicles and in maintaining intracellular cholesterol homeostasis. (UniProt, O75503)

Open in Phaseline: the race on CLN5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NeurogeneNGN-101
Gene therapy for CLN5 deficiency delivered via intracerebroventricular and intravitreal in
CLN5Phase 1Neuronal Ceroid Lipofuscinosis CLN5Nov 2028

Conditions

Neuronal Ceroid Lipofuscinosis CLN5 (1)

Modalities

other (1)

Companies

Neurogene (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.